07/11/2018 14:00:00

GeoVax Presenting at Upcoming Scientific Conferences

Plug & Play Platform Continues to be Recognized for Distinct Benefits

ATLANTA, GA, Nov. 07, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that it will be represented during presentations at the following upcoming scientific conferences.

Fourth International Conference on Vaccines Research and Development, Baltimore, Nov. 12-14

Farshad Guirakhoo, PhD, GeoVax Chief Scientific Officer, will deliver an oral presentation entitled, Development of Vaccines for Infectious Diseases and Cancer Using a Novel MVA-VLP “Plug & Play” Vector Platform; Preclinical Efficacy for Ebola, Lassa Fever and Zika as examples for single dose vaccines. In this talk, the most relevant single-dose vaccine efficacy data, including characterization of humoral and T cell responses, for three different pathogens (Ebola, Lassa and Zika) will be presented as examples for a broad utility of the platform for other indications such as malaria, HPV, HBV and cancer immunotherapy. Dr. Guirakhoo will also serve as Chair for the conference breakout session on Emerging and Re-emerging Diseases on November 14.

World Vaccine & Immunotherapy Congress, San Diego, Nov. 28-30

During this conference, Dr. Guirakhoo will deliver an oral presentation entitled, A Novel Approach for Developing Single Dose and Safe Vaccines for Emerging Infectious Diseases.  In this talk, data for Ebola, Lassa and Zika vaccines, pathogens selected from three different families of viruses, will demonstrate GeoVax’s capability of developing safe and effective single-dose vaccines for many known emerging and re-emerging diseases, as well as for pathogens currently unknown to cause human disease (“Disease X”) with potential for a serious international epidemic. Many of these are included in the “Blueprint List of Priority Diseases” published by the World Health Organization (WHO); with explicit and urgent calls by WHO for accelerated research and development for vaccines and therapeutics. 

 About GeoVax

GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. GeoVax was the winner of the 2018 “Best Biotech” Vaccine Industry Excellence Awards, a finalist for the 2018 “Best Prophylactic Vaccine” Award for its Zika vaccine at the World Vaccine Congress, as well as a finalist for Pipelines of Promise at Buzz of Bio 2018. The Company’s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.

Contact: 

GeoVax Labs, Inc.

investor@geovax.com

678-384-7220

299982_GeoVaxLogo.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Apr
I:SP500
  Hejsa.   Lige lidt læsestof til påsken.   Langsigtet konjunktur:   Overraskende stigning i de le..
48
18 Apr
 
Jeg har modtaget flg. fra Delfin : "Nå, så er jeg blokeret på EI. Hvorfor ved jeg ikke. Jeg har ikke..
37
17 Apr
VELO
  Den eneste TA-ekspert var for mig alpehue, og nogle ganske få andre. Langt de fleste, som udtaler ..
28
15 Apr
VELO
Solen skinner++Envarsus viser vejen med endnu engang rigtig gode data. https://www.ncbi.nlm.nih.gov..
24
17 Apr
 
EI hvorfor har I slettet mit indlæg 414414 og hele debatten om hvad en moderater bør blande sig i ? ..
21
20 Apr
NOVO-B
En lille påskehilsen fra Alpe, med mulighed for Novo.   https://invst.ly/al3nf  
19
21 Apr
NOVO-B
Det var bare mig, der havde spurgt Alpe om en streg på Novo, hvorefter jeg modtog dette, og gerne må..
16
17 Apr
TEVA
Den er også svær lige nu fordi mange korte og lange signaler krydser ind over hinanden lige nu. Men ..
11
15 Apr
VWS
Vestas i 600.. 😊 Det er en stor dag... Tillykke til de tålmodige og trofaste aktionærer.. Endelig ..
11
20 Apr
ZEAL
Nedenfor er en artikle fra Ritzau fra 2018 som gennemgår situationen med Zealand Pharmas tyske samar..
10

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Sprint Corp. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 April 2019 02:03:17
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB3 - 2019-04-22 03:03:17 - 2019-04-22 02:03:17 - 1000 - Website: OKAY